

Expanding the genetic toolbox for engineering commensal clostridia as live bio-therapeutics

Citation for published version (APA):

Zhang, Y. (2024). *Expanding the genetic toolbox for engineering commensal clostridia as live bio-therapeutics*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20241031yz>

Document status and date:

Published: 01/01/2024

DOI:

[10.26481/dis.20241031yz](https://doi.org/10.26481/dis.20241031yz)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Scientific and Societal Impact

The research presented in this thesis promotes advancements in the field of live bio-therapeutics, particularly focusing on the genetic engineering of commensal *Clostridium* species. Live bio-therapeutics, which include living mammalian cells and microbes, represent a new approach in medical treatments, providing a platform for novel therapeutic strategies that go beyond the capabilities of traditional small molecules and biologics. By leveraging the inherent properties of living organisms, live bio-therapeutics can modulate host physiological processes in more dynamic and responsive ways.

Scientific Impact

A major scientific contribution of this thesis is the expansion of the genetic toolkit for *Clostridium* species, particularly *C. sporogenes* and *C. butyricum*. These tools include:

1. **Molecular Vectors and Gene Regulation:** The development of new molecular vectors and promoter libraries, including strong synthetic promoters, enhances our ability to regulate gene expression rationally. The thesis also reports the optimization of tetracycline-inducible systems and the identification of effective non-canonical start codons in clostridia. These advancements facilitate the controlled expression of therapeutic genes, which is vital for tailoring the therapeutic functions of engineered clostridia and ensuring efficacy in therapeutic applications.
2. **Genome Engineering:** The introduction and refinement of CRISPR-Cas9 and CRISPR-Cas12a systems tailored for clostridia allow for efficient and precise genome manipulations. This includes large-gene deletions, integrations, and the development of multi-gene constructs, which are essential for creating sophisticated genetic circuits. The use of native-cryptic plasmids provides an antibiotic-free method for stable overexpression of gene products in *Clostridium* applications.

The expanded genetic toolkit enables the stable production and delivery of therapeutic proteins, which has several implications:

1. **Cancer Therapy:** Engineered *Clostridium* strains, such as *C. sporogenes* expressing two pro-inflammatory cytokines, interleukin-2 and granulocyte macrophage-colony stimulating factor, and pro-drug converting enzymes, hold promise for targeted cancer therapies. The

ability of these bacteria to selectively germinate in hypoxic tumor environments can be harnessed to deliver therapeutic agents directly to tumors, potentially enhancing treatment efficacy and reducing side effects.

2. **Vaccination:** The potential development of *Clostridium* oral-spore vaccination systems represents a novel approach to vaccination. The ability to produce and deliver recombinant antigen proteins via intestinal germination of *Clostridium* spores opens new avenues for creating effective and stable oral vaccines.
3. **Probiotic Treatments:** The engineering of probiotic *C. butyricum* for stable overexpression of therapeutic proteins, such as an anti-inflammatory cytokine, interleukin-10, demonstrates potential for enhancing probiotic-mediated therapies. These treatments could play a significant role in managing intestinal diseases, such as inflammatory bowel disease and pathogen infections.

Societal Impact

The advancements in *Clostridium* bio-therapeutics outlined in this thesis have the potential to transform medical treatments for a wide range of conditions:

1. **Personalized Medicine:** The ability to engineer commensal clostridia that can be tailored to individual patients' needs aligns with the growing trend towards personalized medicine. Such treatments can be customized based on the patient's specific genetic and microbiome profiles, leading to more effective and targeted therapies.
2. **Improved Cancer Treatment:** The use of oncolytic clostridia for cancer therapy offers a novel approach that could complement existing treatments. By targeting the hypoxic regions of tumors, these engineered bacteria can deliver therapeutic agents directly to cancer cells, potentially improving treatment outcomes and reducing the burden of chemotherapy and radiation therapy.
3. **Enhanced Vaccination Strategies:** *Clostridium* oral-spore vaccination systems could change vaccine administration, particularly in regions with limited healthcare infrastructure. These systems are stable, do not require specially environmental storage (e.g., refrigerator and

freezer), and can be easily administered, making them ideal for mass vaccination campaigns in developing countries.

The development of *Clostridium* bio-therapeutics may also raise important ethical and regulatory considerations:

1. **Biosafety and Containment:** Ensuring the safety of engineered clostridia is paramount. The incorporation of biocontainment mechanisms and visible reporters, as highlighted in this thesis, addresses some of these concerns by facilitating the tracking and containment of live bio-therapeutics within the host.
2. **Regulatory Frameworks:** As live bio-therapeutics move closer to clinical application, robust regulatory frameworks will be needed to oversee development, testing, and deployment of *Clostridium* bio-therapeutics. This includes guidelines for genetic modifications, safety testing, and long-term monitoring of therapeutic efficacy and potential side effects.

In conclusion, the expansion of genetic tools for *Clostridium* species not only paves the way for innovative treatments but also promises to make these treatments more accessible, cost-effective, and tailored to individual patient needs. As research progresses, live bio-therapeutics have the potential to significantly impact healthcare worldwide.